Natco Pharma shares plunged after the company reported a steep fall in fourth-quarter profit, revenue and EBITDA. Weak operating margins an...

Holding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...

Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

JioBlackRock Mutual Fund’s Flexi Cap Fund exited Swiggy and 20 other stocks in March, while adding ICICI Prudential Asset Management Compan...

India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...

Natco Pharma is trading above the neckline of a rounding bottom formation, suggesting a bullish outlook. Experts recommend buying for a tar...

Natco Pharma shares fell as investors booked profits after a sharp rally in the previous session. The stock has been volatile this week, sl...

Natco Pharma shares surged on Wednesday, bouncing back from a three-day decline that followed a US FDA inspection of its API manufacturing ...

Natco’s proposed all-cash deal to acquire nearly 36% of AIHL from minority shareholders is aimed at expanding its presence in South Africa,...

NATCO Pharma faced a sharp decline, with a 37.75% drop in net profit in Q3 to Rs 132.4 crore due to lower formulation exports. Despite a ri...

Natco Pharma, incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 17460.53 crore) operating in pharmaceuticals s...

The buyback proposal will not exceed the maximum size, which represents 5.13% and 5.04% of the aggregate of the total paid-up capital and f...

Natco Pharma has a market cap of Rs 10,367 crore as of March 3, 2023. From its 52-week high of Rs 920, the stock is trading 38% lower at Rs...

Natco is the first company in India to have received its registration approval given by the Central Insecticide Board & Registration Commit...

The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.